Inactief instrument

Andere talen IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Aandelen

ICCM

IL0011224156

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

IceCure Medical : Company Presentation	23/04
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	16/04
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	15/04
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	15/04
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	03/04
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03/04
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	02/04
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	02/04
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	02/04
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	27/03
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	20/03
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	19/03
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	19/03
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	12/03
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech and Services Conference	08/03
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference	07/03
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024	04/03
IceCure Medical Ltd. Announces Results from an Independent Study	04/03
Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging and Interventions Workshop	28/02
Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer	27/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Aandelen

ICCM

IL0011224156

Andere talen

Filters